Lataa...

Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer

Chromosome 17q23 amplification occurs in ~11% of human breast cancers. Enriched in HER2+ breast cancers, the 17q23 amplification is significantly correlated with poor clinical outcomes. In addition to the previously identified oncogene WIP1, we uncover an oncogenic microRNA gene, MIR21, in a majorit...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Nat Commun
Päätekijät: Liu, Yunhua, Xu, Jiangsheng, Choi, Hyun Ho, Han, Cecil, Fang, Yuanzhang, Li, Yujing, Van der Jeught, Kevin, Xu, Hanchen, Zhang, Lu, Frieden, Michael, Wang, Lifei, Eyvani, Haniyeh, Sun, Yifan, Zhao, Gang, Zhang, Yuntian, Liu, Sheng, Wan, Jun, Huang, Cheng, Ji, Guang, Lu, Xiongbin, He, Xiaoming, Zhang, Xinna
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group UK 2018
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6226492/
https://ncbi.nlm.nih.gov/pubmed/30413718
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-018-07264-0
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!